-
Je něco špatně v tomto záznamu ?
Age-Dependent Progression in Lung Pathophysiology can be Prevented by Restoring Fatty Acid and Ceramide Imbalance in Cystic Fibrosis
M. Youssef, JB. De Sanctis, J. Shah, DC. Dumut, M. Hajduch, BJ. Petrof, D. Radzioch
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
2433990
CIHR - Canada
NLK
ProQuest Central
od 2002-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 1997-01-01 do Před 1 rokem
- MeSH
- ceramidy metabolismus MeSH
- cystická fibróza metabolismus patofyziologie MeSH
- mastné kyseliny metabolismus MeSH
- modely nemocí na zvířatech MeSH
- myši knockoutované MeSH
- myši MeSH
- pletysmografie MeSH
- plíce patofyziologie MeSH
- progrese nemoci MeSH
- rezistence dýchacích cest fyziologie MeSH
- stárnutí * MeSH
- věkové faktory MeSH
- vysokoúčinná kapalinová chromatografie MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
PURPOSE: Cystic fibrosis (CF) is a progressive disease which causes a continuous decline in lung capacity with age. Our study aimed to investigate the age-dependent deterioration in lung function and the effects of treatment with Fenretinide formulation (LAU-7b) in Cftr knockout (KO) mice. METHODS: Non-invasive whole-body plethysmography (WBP) was done to measure the baseline lung functions of KO and wild-type (WT) mice at the ages of 2 and 4 months. Mice were then treated for 21 days with PBS or 10 mg/kg/day LAU-7b initiated at 4 and 7 months. Standard airway resistance measurements, haematoxylin and eosin staining, and analysis of lipids, and markers of oxidation were performed. RESULTS: The 4- and 7-month-old KO mice had significantly higher lung enhanced pause (Penh) and resistance values than age-matched WT mice and 2-month-old KO mice. Likewise, analysis of ceramides showed that PBS-treated mice had higher levels of long-chain ceramides (LCCs; C14-C18) and lower levels of very-long-chain ceramides (VLCCs; C24-C26) compared to LAU-7b-treated mice. Cftr KO mice displayed markedly greater inflammatory cell infiltration and epithelial hyperplasia at the ages of 2, 4, and 7 months compared to WT. LAU-7b treatment significantly diminished this cellular infiltration and epithelial hyperplasia compared to PBS-treated mice. CONCLUSION: Our results demonstrate a progressive age-dependent decline in lung function in Cftr KO mice. Treatment with LAU-7b corrects the lipid imbalance observed in the aging KO and WT mice and, more importantly, inhibits the age-dependent deterioration in lung physiology and histopathology.
Department of Human Genetics McGill University McGill University Montreal QC Canada
Department of Pharmacology and Therapeutics McGill University Montreal QC Canada
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026696
- 003
- CZ-PrNML
- 005
- 20211026132705.0
- 007
- ta
- 008
- 211013s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00408-020-00353-2 $2 doi
- 035 __
- $a (PubMed)32306138
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Youssef, Mina $u Department of Human Genetics, McGill University, McGill University, Montreal, QC, Canada $u Program in Infectious Diseases and Immunity in Global Health, McGill University Health Centre, 1001 Decarie Boulevard, Room EM3-3211, Montreal, QC, H4A 3J1, Canada
- 245 10
- $a Age-Dependent Progression in Lung Pathophysiology can be Prevented by Restoring Fatty Acid and Ceramide Imbalance in Cystic Fibrosis / $c M. Youssef, JB. De Sanctis, J. Shah, DC. Dumut, M. Hajduch, BJ. Petrof, D. Radzioch
- 520 9_
- $a PURPOSE: Cystic fibrosis (CF) is a progressive disease which causes a continuous decline in lung capacity with age. Our study aimed to investigate the age-dependent deterioration in lung function and the effects of treatment with Fenretinide formulation (LAU-7b) in Cftr knockout (KO) mice. METHODS: Non-invasive whole-body plethysmography (WBP) was done to measure the baseline lung functions of KO and wild-type (WT) mice at the ages of 2 and 4 months. Mice were then treated for 21 days with PBS or 10 mg/kg/day LAU-7b initiated at 4 and 7 months. Standard airway resistance measurements, haematoxylin and eosin staining, and analysis of lipids, and markers of oxidation were performed. RESULTS: The 4- and 7-month-old KO mice had significantly higher lung enhanced pause (Penh) and resistance values than age-matched WT mice and 2-month-old KO mice. Likewise, analysis of ceramides showed that PBS-treated mice had higher levels of long-chain ceramides (LCCs; C14-C18) and lower levels of very-long-chain ceramides (VLCCs; C24-C26) compared to LAU-7b-treated mice. Cftr KO mice displayed markedly greater inflammatory cell infiltration and epithelial hyperplasia at the ages of 2, 4, and 7 months compared to WT. LAU-7b treatment significantly diminished this cellular infiltration and epithelial hyperplasia compared to PBS-treated mice. CONCLUSION: Our results demonstrate a progressive age-dependent decline in lung function in Cftr KO mice. Treatment with LAU-7b corrects the lipid imbalance observed in the aging KO and WT mice and, more importantly, inhibits the age-dependent deterioration in lung physiology and histopathology.
- 650 _2
- $a věkové faktory $7 D000367
- 650 12
- $a stárnutí $7 D000375
- 650 _2
- $a rezistence dýchacích cest $x fyziologie $7 D000403
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a ceramidy $x metabolismus $7 D002518
- 650 _2
- $a vysokoúčinná kapalinová chromatografie $7 D002851
- 650 _2
- $a cystická fibróza $x metabolismus $x patofyziologie $7 D003550
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a mastné kyseliny $x metabolismus $7 D005227
- 650 _2
- $a plíce $x patofyziologie $7 D008168
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši knockoutované $7 D018345
- 650 _2
- $a pletysmografie $7 D010991
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a De Sanctis, Juan B $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
- 700 1_
- $a Shah, Juhi $u Program in Infectious Diseases and Immunity in Global Health, McGill University Health Centre, 1001 Decarie Boulevard, Room EM3-3211, Montreal, QC, H4A 3J1, Canada $u Department of Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada
- 700 1_
- $a Dumut, Daciana Catalina $u Program in Infectious Diseases and Immunity in Global Health, McGill University Health Centre, 1001 Decarie Boulevard, Room EM3-3211, Montreal, QC, H4A 3J1, Canada $u Department of Medicine, Division of Experimental Medicine, McGill University, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada
- 700 1_
- $a Hajduch, Marian $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
- 700 1_
- $a Petrof, Basil J $u Department of Medicine, Division of Experimental Medicine, McGill University, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada $u Meakins-Christie Laboratories, Translational Research in Respiratory Diseases Program, Department of Medicine, McGill University Health Centre, Montreal, QC, Canada
- 700 1_
- $a Radzioch, Danuta $u Department of Human Genetics, McGill University, McGill University, Montreal, QC, Canada. danuta.radzioch@mcgill.ca $u Program in Infectious Diseases and Immunity in Global Health, McGill University Health Centre, 1001 Decarie Boulevard, Room EM3-3211, Montreal, QC, H4A 3J1, Canada. danuta.radzioch@mcgill.ca $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. danuta.radzioch@mcgill.ca $u Department of Medicine, Division of Experimental Medicine, McGill University, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada. danuta.radzioch@mcgill.ca
- 773 0_
- $w MED00003159 $t Lung $x 1432-1750 $g Roč. 198, č. 3 (2020), s. 459-469
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32306138 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026132712 $b ABA008
- 999 __
- $a ok $b bmc $g 1715436 $s 1147203
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 198 $c 3 $d 459-469 $e 20200418 $i 1432-1750 $m Lung $n Lung $x MED00003159
- GRA __
- $a 2433990 $p CIHR $2 Canada
- LZP __
- $a Pubmed-20211013